Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis.
Prostate Cancer Prostatic Dis
; 27(3): 393-403, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38267540
ABSTRACT
INTRODUCTION:
Androgen receptor targeted agents (ARTA) have increasingly been incorporated into treatment regimens for various stages of prostate cancer. Patients are living longer with prostate cancer, and thus have a higher cumulative exposure to the treatment and its accompanying side effects, especially those of cardiovascular disease. We aim to assess the differences in the incidence of cardiac-related adverse events after treatment of prostate cancer with ARTA versus placebo.METHODS:
Three databases were thoroughly searched for relevant articles. The PICOS model was used to frame our clinical question, with which 2 independent authors went through several rounds of screening to select the final included studies. Meta-analysis was done using the Cochran-Mantel-Haenszel Method. Quality assessment was carried out with the Cochrane Risk of Bias tool RoB 2.RESULTS:
The use of ARTA in prostate cancer increases the incidence of cardiac-related adverse events (RR 1.56, 95% CI 1.29-1.90, p < 0.00001), such as hypertension (RR 1.69, 95% CI 1.46-1.97, p < 0.00001), ischaemic heart disease (RR 1.84, 95% CI 1.36-2.50, p < 0.0001), and arrhythmia (RR 1.38, 95% CI 1.11-1.71, p = 0.004), although this did not manifest in an increased incidence of cardiac arrests/deaths (RR 1.28, 95% CI 0.87-1.88, p = 0.21).DISCUSSION:
ARTA increases the risk of cardiac-related adverse events, hypertension, ischaemic heart disease and arrhythmia. Armed with this knowledge, we will be better poised to manage cardiac risks accordingly and involve a cardiologist as required when starting patients on ARTA.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Doenças Cardiovasculares
/
Receptores Androgênicos
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
/
Male
Idioma:
En
Revista:
Prostate Cancer Prostatic Dis
Assunto da revista:
ENDOCRINOLOGIA
/
NEOPLASIAS
/
UROLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Singapura